TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22639013
Drug: Sodium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium intake >4.5 g/day
Study: 19224430
Drug: PIO (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIO (45 mg) + placebo
Study: 19224430
Drug: SIMVA (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIMVA (40 mg) + placebo
Study: 19224430
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms (PIO, SIMVA, PIO + SIMVA)
Study: 17568648
Drug: Transient VEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transient VEP in response to isoluminant chromatic (L-M) sinewave gratings
Study: 7614520
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg (titrated up to 40 mg) once in the evening
Study: 25608587
Drug: Isoniazid treatment
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid treatment
Study: 28332191
Drug: Combined Er:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Er:YAG (160 mJ/pulse, 10 Hz) and Nd:YAG laser (100 mJ/pulse, 20 Hz) therapy
Study: 21444654
Drug: Robotic-assisted gait
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-assisted gait training (20 sessions in the first 4 weeks of inpatient therapy)
Study: 17542202
Drug: Fluoride toothpaste
Normalized name: sodium fluoride Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride toothpaste (Elmex sensitive toothpaste, 1400 ppm F) plus fluoride mouthrinse (Elmex sensitive rinse containing 250 ppm F) used twice a day.
Study: 17542202
Drug: Placebo mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouthrinse without fluoride used twice a day with the same fluoride toothpaste.
Study: 15509203
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sublingual sildenafil
Study: 11827307
Drug: ELISA alone
Normalized name: pseudopterogorgia elisabethae extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELISA alone or in combination with SPT
Study: 9290020
Drug: Sex hormone
Normalized name: Sex hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormone receptors
Study: 1764956
Drug: Fendiline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fendiline (75 mg twice daily)
Study: 6805031
Drug: Ethanol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.75 g/kg) + Naloxone (0.4 mg)
Study: 6805031
Drug: Ethanol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.75 g/kg) + Saline
Study: 30943275
Drug: Azilsartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azilsartan (20 mg/day)
Study: 23942133
Drug: Oral etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral etoricoxib
Study: 25262192
Drug: Oral gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral gabapentin
Study: 12773446
Drug: Follitropin beta
Normalized name: Follitropin Beta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin beta administered by a pen device
Study: 12773446
Drug: Follitropin alpha
Normalized name: follitropin alpha
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin alpha administered by a conventional syringe
Study: 1492932
Drug: Eflornithine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine (400 mg/kg daily, continuous intravenous infusion)
Study: 1492932
Drug: Cotrimoxazole (3.84
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (3.84 g twice daily, intravenously)
Study: 1492932
Drug: Eflornithine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine (400 mg/kg daily)
Study: 1492932
Drug: Cotrimoxazole (7.68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (7.68 g daily)
Study: 26936480
Drug: Youth mentor-led
Normalized name: Mentol
DrugBank: Levomenthol (DB00825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Youth mentor-led nutritional intervention (BHCK); bi-weekly interactive sessions delivered by 16 youth leaders.
Study: 19249751
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine self-administration (1.0 mg/kg)
Study: 8098220
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of bisoprolol daily for two weeks
Study: 3101553
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate eye ointment
Study: 31568587
Drug: Low-dose exercise
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exercise (150 minutes per week)
Study: 31568587
Drug: High-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exercise (300 minutes per week)
Study: 28551073
Drug: Ixekizumab every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab every 4 weeks (80 mg after a 160 mg starting dose)
Study: 28551073
Drug: Ixekizumab every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab every 2 weeks (80 mg after a 160 mg starting dose)
Study: 22846777
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg liraglutide
Study: 27282158
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg liraglutide
Study: 27282158
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg liraglutide
Study: 21905751
Drug: Mixed nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed nuts consumption (30 g/day)
Study: 9393746
Drug: Nicotinamide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (80 mg/kg)
Study: 24005608
Drug: Mekabu fucoidan
Normalized name: Fucidin
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mekabu fucoidan (MF) 300 mg/d
Study: 15298073
Drug: NCX-701 (nitric
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCX-701 (nitric oxide-releasing derivative of paracetamol)
Study: 11703886
Drug: Serotonin agents
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin agents
Study: 8990428
Drug: Partially home-based
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially home-based moderate-intensity aerobic exercise program (30 minutes, 3-4 times weekly at 70% of estimated maximal heart rate)
Study: 8491069
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg ibuprofen and 15 mg/kg acetaminophen
Study: 24368060
Drug: early modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: early modified IPS intervention in addition to treatment-as-usual
Study: 24368060
Drug: treatment-as-usual alone
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment-as-usual alone
Study: 17967917
Drug: DHA-PQ (piperaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-PQ (piperaquine phosphate at 20 mg/kg/day for 3 days)
Study: 17967917
Drug: CQ-SP (chloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQ-SP (chloroquine at 10 mg base/kg/day for 3 days with a single dose of sulfadoxine-pyrimethamine)
Study: 14655921
Drug: Novel Bilevel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel Bilevel (NBL) therapy
Study: 10394523
Drug: Ultrashort stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrashort stimulation (gonadotropin releasing hormone agonist plus hMG or FSH)
Study: 6429406
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with EAA (2.3 g of nitrogen per day)
Study: 6429406
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with ENAA (11.3 g of nitrogen per day)
Study: 26833396
Drug: VR exposure
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR exposure therapy (n = 50)
Study: 18046926
Drug: Prandial premixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prandial premixed insulin analogues (70% or 75% basal and 30% or 25% rapid-acting insulin analogue)
Study: 18046926
Drug: Prandial premixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prandial premixed insulin analogues (50% basal and 50% rapid-acting insulin analogue)
Study: 18046926
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin analogues
Study: 11921591
Drug: Paracetamol (washout
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (washout period)
Study: 3047900
Drug: Mucoregulatory agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucoregulatory agents
Study: 28355362
Drug: 10% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% hydrogen peroxide (Oral B 3D White - Oral-B)
Study: 23698019
Drug: 1 injection
Normalized name: vitamin K1 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 injection of lidocaine (0.5%)
Study: 23698019
Drug: 5 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 injections of lidocaine (0.5%)
Study: 23698019
Drug: 1 injection
Normalized name: vitamin K1 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 injection of saline (NaCl 0.9%)
Study: 23698019
Drug: 5 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 injections of saline (NaCl 0.9%)
Study: 20518813
Drug: Effervescent tablets
Normalized name: Hydralyte Effervescent Tablets Berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent tablets and ultrasonic device
Study: 18348774
Drug: Tinidazole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (single dose of 50 mg/kg)
Study: 18348774
Drug: Nitazoxanide (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (7.5 mg/kg twice a day for 3 days)
Study: 11954681
Drug: All interventions
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All interventions including the most important and adjunctive ones
Study: 7650235
Drug: Butorphanol nasal
Normalized name: butorphanol nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol nasal spray (1 mg)
Study: 7650235
Drug: Butorphanol nasal
Normalized name: butorphanol nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol nasal spray plus sumatriptan (1 mg butorphanol + 6 mg SC sumatriptan)
Study: 7650235
Drug: Butorphanol nasal
Normalized name: butorphanol nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol nasal spray
Study: 410176
Drug: no additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: no additional therapy
Study: 30776911
Drug: Psychiatric health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric health and substance use issues (depression, anxiety, drug use)
Study: 28668399
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity statin therapy (atorvastatin 80mg/day)
Study: 28668399
Drug: Moderate intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate intensity statin therapy (atorvastatin 20mg/day)
Study: 21665007
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of sertraline plus 2 g/day omega‐3 fatty acids
Study: 21665007
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of sertraline plus 2 g/day corn oil placebo capsules
Study: 8422085
Drug: l-deprenyl (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-deprenyl (5 mg b.i.d.)
Study: 3655855
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (CMF, CAF, CAFVP)
Study: 3655855
Drug: Chemotherapy (overall)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (overall)
Study: 31987106
Drug: Antidiabetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic treatment only (group C)
Study: 27102821
Drug: Soluble RSV
Normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble RSV fusion protein (sF) with GLA adjuvant at highest dosage level
Study: 20735858
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution plus Saccharomyces boulardii
Study: 20735858
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution plus a compound containing Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum and Saccharomyces boulardii
Study: 20735858
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration therapy plus placebo
Study: 18474338
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without nesiritide
Study: 10457394
Drug: Cerebrospinal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrospinal fluid (CSF) filtration daily over five days (group A)
Study: 10457394
Drug: Riluzole treatment
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole treatment only (group B)
Study: 2104077
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g sucralfate daily at bedtime
Study: 2104077
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g sucralfate four times daily (q.d.s.)
Study: 350500
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ketoprofen twice daily
Study: 21616771
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate (H-CHO; 60% of daily caloric intake)
Study: 21616771
Drug: Low carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low carbohydrate (L-CHO; 30% of daily caloric intake)
Study: 16968916
Drug: Malarone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malarone (250 mg atovaquone plus 100 mg proguanil hydrochloride) daily from 1 day before entering the endemic area to 7 days after leaving the endemic area
Study: 15226514
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment continued for 2 years
Study: 15226514
Drug: Infliximab infusions
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab infusions every 8 weeks
Study: 15226514
Drug: Long-term model
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term model for infliximab treatment
Study: 6719982
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acebutolol and nifedipine
Study: 26045552
Drug: Myrtus communis
Normalized name: MYRTUS COMMUNIS TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrtus communis L. freeze-dried aqueous extract (1000 mg/d)
Study: 26045552
Drug: Omeprazol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazol (20 mg/d)
Study: 26045552
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Myrtus communis and Omeprazol
Study: 25457739
Drug: Behavioral therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapies
Study: 20103724
Drug: Topical perillyl
Normalized name: perilla frutescens top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical perillyl alcohol (POH) cream, low dose (0.76% w/w)
Study: 20103724
Drug: Topical perillyl
Normalized name: perilla frutescens top
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical perillyl alcohol (POH) cream, high dose
Study: 16140708
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 mg/day for 4 weeks, followed by lovastatin 40 mg/day for 20 weeks
Study: 30990099
Drug: Contraceptive vaginal
Normalized name: VCF 4% Contraceptive Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive vaginal ring containing ethinylestradiol 3.47 mg and etonogestrel 11.00 mg
Study: 30990099
Drug: Contraceptive vaginal
Normalized name: VCF 4% Contraceptive Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive vaginal ring containing ethinylestradiol 2.7 mg and etonogestrel 11.7 mg
Study: 29649978
Drug: Personalized objects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized objects (e.g., cigarette, paper)
Study: 24268886
Drug: AUDIT administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUDIT administered at baseline with a cut-point of 8 or above
Study: 24268886
Drug: AUDIT administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUDIT administered at baseline
Study: 24268886
Drug: Past amphetamine-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Past amphetamine-type stimulant (ATS) use
Study: 22433034
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group) (CR)
Study: 20708496
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity intervention (20 min of daily exercise in the classroom)
Study: 18570266
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg Pycnogenol per day at meals
Study: 1906830
Drug: 0.03 mg
Normalized name: biotin 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg estriol vaginal tablets
Study: 6227756
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg trimethoprim at night
Study: 6227756
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg methenamine hippurate every 12 hours
Study: 6227756
Drug: Topical povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical povidone-iodine solution, cleansing twice daily
Study: 24365961
Drug: BeZuHG (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: BeZuHG (early discharge followed by home treatment service)
Study: 18093207
Drug: Vildagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (100 mg daily)
Study: 19476473
Drug: Metformin (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (titrated to 1500 mg daily)
Study: 17502494
Drug: Aldosterone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone infusion (3.3 to 55 pmol/min per 1000 mL forearm volume)
Study: 17502494
Drug: Aldosterone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone infusion (55 pmol/1000 mL per min)
Study: 17502494
Drug: Oral fludrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fludrocortisone (0.3 mg/d for 2 weeks)
Study: 11641371
Drug: Oral ribose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ribose supplementation (4 doses/day at 4 g/dose)
Study: 7989402
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate syrup 70 mg/ml administered 20-40 min prior to procedure
Study: 24006749
Drug: Laminaria jam
Normalized name: Laminaria digitata preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laminaria jam enriched with chromium (20 g daily containing 280 microg of iodine and 66 microg of chromium)
Study: 24006749
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (comparison group)
Study: 18356327
Drug: Cocoa flavanol-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanol-containing dark chocolate bar with added sterol esters (1.1 g sterol esters per bar)
Study: 10408591
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with diuretic (hydrochlorothiazide)
Study: 10408591
Drug: Both ACE
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both ACE inhibitors
Study: 1979188
Drug: Medicamentous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicamentous treatment alone (control group)
Study: 28056024
Drug: Single-dose 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose 400 mg albendazole (for STH-positive mothers)
Study: 23373620
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg aspirin for 30 days and 180 mg ticagrelor for 1 year
Study: 21294929
Drug: Xylose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylose (50 g)
Study: 19696440
Drug: Sublingual house
Normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual house dust mite (HDM) immunotherapy
Study: 17355733
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg once daily for 6 months)
Study: 17355733
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily oral for 6 months)
Study: 9876598
Drug: Model I
Normalized name: VIVI Cap Insulin Temperature Shield Multi-Model Insulin Pen Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model I (cumulative percentage of paracetamol dissolved)
Study: 3072180
Drug: Behavioral interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral interventions (relaxation and biofeedback therapies)
Study: 26571887
Drug: Medication (estazolam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (estazolam 1 mg orally)
Study: 23383959
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg kg(‐1))
Study: 23383959
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 ml)
Study: 20189611
Drug: AST-120 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AST-120 treatment (6 g/d)
Study: 25694653
Drug: LPV/r monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r monotherapy
Study: 19320241
Drug: Standard triple-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple-drug regimen
Study: 12818245
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy (warfarin 10, 7.5, and 5 mg for three consecutive days)